What is Citigroup's price target for SILK?

Citigroup's latest stated price target for Silk Road Medical Inc. (SILK) is $8, from its action on Oct 11, 2023.

What is Citigroup's rating on SILK?

Citigroup rates SILK Sell, a bearish rating, as of Oct 11, 2023.

When did Citigroup last change its view on SILK?

On Oct 11, 2023, Citigroup downgrades to Sell from Buy, price target $35 to $8.

Citigroup SILK price target and rating history

Silk Road Medical Inc. (SILK) · Health Care

Citigroup rates Silk Road Medical Inc. (SILK) Sell with a $8 price target, as of its latest action on Oct 11, 2023. It has published 7 rating actions on SILK since October 2021, including 3 upgrades and 3 downgrades.

Current rating: Sell
Price target: $8
Median target, all firms: Too few
Actions on SILK: 7

Citigroup price target on SILK

Citigroup price target on SILK, each point a stated target, October 2021 to October 2023.

Every Citigroup rating on SILK

Oct 11, 2023
DowngradeCitigroup downgrades to Sell from Buy, price target $35 to $8
Apr 3, 2023
UpgradeCitigroup upgrades to Buy from Neutral, price target $50
Mar 10, 2023
UpgradeCitigroup upgrades to Neutral from Sell, price target $50
Jul 11, 2022
DowngradeCitigroup downgrades to Sell from Neutral, price target $33
Feb 25, 2022
ReiterateCitigroup cuts its price target to $37 from $45, keeps Neutral
Nov 19, 2021
UpgradeCitigroup upgrades to Neutral from Sell, price target $50
Oct 1, 2021
DowngradeCitigroup downgrades to Sell from Neutral, price target $50

Questions about Citigroup and SILK

What is Citigroup's price target for SILK?: Citigroup's latest stated price target for Silk Road Medical Inc. (SILK) is $8, from its action on Oct 11, 2023.
What is Citigroup's rating on SILK?: Citigroup rates SILK Sell, a bearish rating, as of Oct 11, 2023.
When did Citigroup last change its view on SILK?: On Oct 11, 2023, Citigroup downgrades to Sell from Buy, price target $35 to $8.

More SILK rating histories

All Citigroup ratings SILK news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.